New treatment for myeloma receives second negative recommendation across Europe

Plitidepsin (Aplidin®), a new medicine for the treatment of relapsed and refractory myeloma, has received a second negative recommendation from the Committee for Medicinal Products for Human Use (CHMP). This decision means that plitidepsin is very unlikely to be made available to patients across Europe. This upholds a previous negative recommendation from the CHMP, which was reviewed following an appeal by the pharmaceutical company Pharma Mar. The CHMP is the scientific advisory committee of the European Medicines Agency (EMA), the European licensing body. It provides advice to the European Commission on new medicines going through the licensing process and whether